Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.

被引：0
|
作者：
Freedland, Stephen J.
Hong, Agnes
El-Chaar, Nader N.
De Hoedt, Amanda Marie
Kim, Janet
Ramaswamy, Krishnan
Gu, Lin
Polascik, Thomas
机构：
[1] Cedars Sinai Med Ctr, Ctr Integrated Res Canc & Lifestyle, Los Angeles, CA USA
[2] Astellas Pharma Inc, Northbrook, IL USA
[3] Pfizer Inc, New York, NY USA
[4] Vet Affairs Hlth Care Syst, Urol Sect, Dept Surg, Durham, NC USA
[5] Astellas Pharma Global Dev Inc, Northbrook, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17081
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a US health insurance database.
    Swami, Umang
    Hong, Agnes
    El-Chaar, Nader N.
    Nimke, David
    Ramaswamy, Krishnan
    Bell, Elizabeth J.
    Sandin, Rickard
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Real-world economic burden of patients with metastatic castration-sensitive prostate cancer (mCSPC)
    Kaye, Deborah
    Khilfeh, Ibrahim
    Muser, Erik
    Morrison, Laura
    Urosevic, Ana
    Kinkead, Frederic
    Lefebvre, Patrick
    Pilon, Dominic
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 64 - 64
  • [3] Barriers and facilitators to first-line (1L) treatment intensification (TI) in metastatic castration-sensitive prostate cancer (mCSPC): The IMPLEMENT study.
    Loeb, Stacy
    Agarwal, Neeraj
    El-Chaar, Nader N.
    de Ruiter, Laura
    Kim, Janet
    Mack, Jessica
    Bland, Christopher S.
    Rich-Zendel, Sarah
    Joo, Jin Su
    Dyson, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 224 - 224
  • [4] Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study
    Tagawa, S. T.
    Sandin, R.
    Sah, J.
    Mu, Q.
    Freedland, S. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S541 - S542
  • [5] Real-world (RW) prevalence of adverse events (AEs) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC).
    Swami, Umang
    Xie, Bin
    Ramaswamy, Krishnan
    El-Chaar, Nader N.
    Gao, Wei
    Yang, Hongbo
    Wang, Yao
    Young, Christopher
    Mucha, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) -doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).
    Parrish, Joshua
    Polascik, Thomas J.
    Hong, Agnes
    El-Chaar, Nader N.
    De Hoedt, Amanda Marie
    Kim, Janet
    Eve, Claire Trustram
    Touya, Maelys
    Ramaswamy, Krishnan
    Gu, Lin
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 145 - 145
  • [7] Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.
    Freedland, Stephen J.
    Sandin, Rickard
    Sah, Janvi
    Emir, Birol
    Mu, Qiao
    Ratiu, Anna
    Hong, Agnes
    Serfass, Lucile
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer
    Swami, Umang
    Xie, Bin
    Young, Christopher
    Ramaswamy, Krishnan
    El-Chaar, Nader
    Gao, Wei
    Yang, Hongbo
    Wang, Yao
    Mucha, Lisa
    PROSTATE, 2024,
  • [9] Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
    Smyth, Emily Nash
    Whipple, Samuel
    Guinter, Mark
    Haddad, Nadine
    Piao, Wenxian
    Cui, Zhanglin Lin
    Balar, Arjun Vasant
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 55 - 55
  • [10] SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC)
    Swami, U.
    Graf, R. P.
    Nussenzveig, R.
    Fisher, V.
    Tukachinsky, H.
    Li, G.
    Sayegh, N.
    Tripathi, N.
    Thomas, V. Mathew
    Oxnard, G. R.
    Antonarakis, E. S.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1170 - S1170
12345